Seres Therapeutics Inc. (NASDAQ:MCRB) shares saw an uptick in trading volume on Thursday . 443,856 shares traded hands during trading, an increase of 32% from the previous session’s volume of 336,586 shares.The stock last traded at $33.94 and had previously closed at $33.70.

A number of research firms recently commented on MCRB. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Monday, June 13th. Zacks Investment Research lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday. Leerink Swann reaffirmed a “buy” rating and set a $43.00 price objective on shares of Seres Therapeutics in a research note on Thursday, July 14th. FBR & Co reissued a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 8th. Finally, Canaccord Genuity reissued a “buy” rating on shares of Seres Therapeutics in a research note on Sunday, May 29th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. Seres Therapeutics presently has a consensus rating of “Buy” and an average price target of $43.86.

The stock’s market cap is $1.33 billion. The company has a 50-day moving average price of $31.04 and a 200-day moving average price of $28.14.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.02. The firm earned $2.71 million during the quarter, compared to the consensus estimate of $1.25 million. Analysts anticipate that Seres Therapeutics Inc. will post ($1.81) earnings per share for the current year.

In other news, CEO Roger Pomerantz sold 88,211 shares of the business’s stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $29.45, for a total value of $2,597,813.95. Following the sale, the chief executive officer now owns 236,468 shares of the company’s stock, valued at approximately $6,963,982.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ventures Fund 2007 L. Flagship sold 1,000,000 shares of the business’s stock in a transaction on Wednesday, May 25th. The stock was sold at an average price of $27.60, for a total value of $27,600,000.00. The disclosure for this sale can be found here.

Several hedge funds have recently bought and sold shares of MCRB. ProShare Advisors LLC purchased a new stake in Seres Therapeutics during the fourth quarter worth approximately $1,146,000. Morgan Stanley raised its stake in shares of Seres Therapeutics by 225.3% in the fourth quarter. Morgan Stanley now owns 33,758 shares of the company’s stock worth $1,185,000 after buying an additional 23,381 shares during the period. Finally, Jennison Associates LLC raised its stake in shares of Seres Therapeutics by 1.9% in the fourth quarter. Jennison Associates LLC now owns 398,959 shares of the company’s stock worth $13,999,000 after buying an additional 7,259 shares during the period.

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.